Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial

Study limitation reported by the research below: “The non-inferiority design means the study was not powered to detect superiority; the HR of 1.56 trending against the combination arm should be noted clinically even though p=0.200.”